This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Catalyst Pharmaceutical Partners Promotes Steven R. Miller, Ph.D. To Chief Operating Officer

CORAL GABLES, Fla., Jan. 25, 2011 (GLOBE NEWSWIRE) -- Catalyst Pharmaceutical Partners, Inc. (Nasdaq:CPRX) announced today that Steven R. Miller, Ph.D., Catalyst's Chief Scientific Officer, has been promoted to Chief Operating Officer, a new position at Catalyst. Dr. Miller will also retain his position and responsibilities as Catalyst's Chief Scientific Officer.

"Dr. Miller has steadily and successfully taken on more responsibility since joining Catalyst," said Patrick J. McEnany, Catalyst's Chief Executive Officer. "He was responsible for identifying and in-licensing CPP-115, our newest drug candidate, from Northwestern University and in taking that product through an initial series of successful non-clinical studies. We fully expect Dr. Miller to continue to play a key role in the future as part of Catalyst's senior management team."

"I am honored by this show of confidence, proud to be part of this team that is so committed to making a difference, and excited about Catalyst's prospects for the future," said Dr. Miller. "Our company is poised for expansion and growth, and I'm thrilled to have this opportunity."

Dr. Miller has over 20 years of experience in the pharmaceutical industry in a wide range of positions. Prior to joining Catalyst in April of 2007, Dr. Miller spent 15 years with various divisions of Watson Pharmaceuticals, Inc. (Watson), his last position as Executive Director of R&D Operations. In this capacity, Dr. Miller led a multi-site team of 70 employees in the testing of all R&D products for development support and clinical studies, including method validation, stability testing, operation of the R&D pilot plant, assembly of the CMC section of drug applications, in addition to other responsibilities. Dr. Miller held other positions at Watson, including Director of Technology Transfer and Vice President of Research and Product Development of Royce Laboratories, Inc., which was subsequently acquired by Watson. Before joining Royce Laboratories, Dr. Miller was a Group Leader at Dade Behring (formerly Baxter Diagnostics, Inc.), where he led a design team in the development of a new diagnostic analyzer and associated reagents. Dr. Miller also served as an Analytical Chemist at the U.S. Food & Drug Administration.

1 of 2

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 16,943.81 +28.74 0.17%
S&P 500 1,967.57 +2.89 0.15%
NASDAQ 4,415.49 +19.2860 0.44%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto
Advertising Partners

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs